Update for investors of

LUPIN

is currently trading at Rs. 2098.00, up by 7.85 points or 0.38% from its previous closing of Rs. 2090.15 on the BSE. The scrip opened at Rs. 2087.25 and has touched a high and low of Rs. 2098.05 and Rs. 2078.15 respectively. So far 4004 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1774.00 on 07-Apr-2025. Last one week high and low of the scrip stood at Rs. 2119.95 and Rs. 2046.05 respectively. The current market cap of the company is Rs. 95678.79 crore. The promoters holding in the company stood at 46.90%, while Institutions and Non-Institutions held 47.06% and 6.06% respectively. Lupin’s greenhouse gas (GHG) emissions reduction targets have been officially validated by the Science Based Targets initiative (SBTi). These validations cover all three emission scopes - Scope 1, Scope 2, and Scope 3 - aligning with the Paris Agreement to limit global temperature rise to 1.5 degree Celsius. This milestone underscores Lupin’s commitment to sustainability and decisive climate action, positioning the company among a select group that has achieved comprehensive SBTi validation within a year of setting its climate targets. These goals are aligned with the 1.5 degree Celsius pathway and validated under SBTi’s latest guidelines, thereby positioning Lupin as a key participant in the global effort to combat climate change. Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.